Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: New insights attained by mass spectrometry

Journal of Urology

Volumn 187, Issue 5, 2012, Pages 1601-1607

  Van Der Sluis, Tim M ^a   Bui, Hong N ^a   Meuleman, Eric J H ^a   Heijboer, Annemieke C ^a   Hartman, Jeroen F ^b   Van Adrichem, Nick ^c   Boevé, Egbert ^d   De Ronde, Willem ^a   Van Moorselaar, R Jeroen A ^a   Vis, André N ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNLAND HOSPITAL   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

castration; luteinizing hormone; prostatic neoplasms; serum; testosterone

Indexed keywords

ANDROSTENEDIONE; BUSERELIN; DOCETAXEL; GOSERELIN; INHIBIN B; LEUPRORELIN; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CONTROLLED STUDY; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

EID: 84859529884     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.12.063     Document Type: Article

References (30)

1. C. Huggins, C.V. Hodges Studies on prostatic cancer: I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
2. L.W. Riba Subcapsular castration for carcinoma of prostate J Urol 48 1942 384
3. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 1991 502
4. N.J. Vogelzang, G.W. Chodak, M.S. Soloway Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial Zoladex Prostate Study Group Urology 46 1995 220
5. M.S. Soloway, G. Chodak, N.J. Vogelzang et al. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group Urology 37 1991 46
6. Leuprolide versus diethylstilbestrol for metastatic prostate cancer The Leuprolide Study Group N Engl J Med 311 1984 1281
7. W.B. Peeling Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma Urology 33 1989 45
8. N. Mottet, J. Bellmunt, M. Bolla EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572
9. J. Taieb, B. Mathian, F. Millot Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children Clin Chem 49 2003 1381
10. D.A. Herold, R.L. Fitzgerald Immunoassays for testosterone in women: better than a guess? Clin Chem 49 2003 1250
11. W. Rosner, R.J. Auchus, R. Azziz Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement J Clin Endocrinol Metab 92 2007 405
12. H.N. Bui, E.A. Struys, F. Martens Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy Ann Clin Biochem 47 2010 248
13. L.M. Thienpont, K. Van Uytfanghe, S. Blincko State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry Clin Chem 54 2008 1290
14. T.M. van der Sluis, A.N. Vis, R.J. van Moorselaar Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer BJU Int 109 2012 176
15. H.F. Røhl, H.P. Beuke Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer Scand J Urol Nephrol 26 1992 11
16. M.G. Oefelein, R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726
17. O.E. Yri, T. Bjoro, S.D. Fossa Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer Eur Urol 49 2006 54
18. J.H. McDonald, J.A. Calams Extraparenchymal Leydig-like cells: observations following subcapsular orchiectomy J Urol 82 1959 145
19. J. Pinski, S. Xiong, Q. Wang Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer Prostate 71 2011 892
20. S.V. Liu, A.V. Schally, D. Hawes Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists Clin Cancer Res 16 2010 4675
21. S.V. Gonzlez, X.M. Pijuan Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate BJU Int 107 2010 1200
22. A. Zlotta, F.M. Debruyne Expert opinion on optimal testosterone control in prostate cancer Eur Urol Suppl 4 2005 37
23. L. Collette, T. Burzykowski, K.J. Carroll Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals J Clin Oncol 23 2005 6139
24. M. Perachino, V. Cavalli, F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105 2010 648
25. C.C. Schulman, J. Irani, J. Morote Testosterone measurement in patients with prostate cancer Eur Urol 58 2010 65
26. H.H. Young 2nd, J.R. Kent Plasma testosterone levels in patients with prostatic carcinoma before and after treatment J Urol 99 1968 788
27. W.S. Coppage Jr, A.E. Cooner Testosterone in human plasma N Engl J Med 273 1965 902
28. R.J. Shearer, W.F. Hendry, I.F. Sommerville Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer Br J Urol 45 1973 668
29. M.G. Oefelein, A. Feng, M.J. Scolieri Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021
30. J. Morote, A. Orsola, J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290